339 related articles for article (PubMed ID: 25431357)
1. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.
Gragnani L; Fognani E; Piluso A; Boldrini B; Urraro T; Fabbrizzi A; Stasi C; Ranieri J; Monti M; Arena U; Iannacone C; Laffi G; Zignego AL;
Hepatology; 2015 Apr; 61(4):1145-53. PubMed ID: 25431357
[TBL] [Abstract][Full Text] [Related]
2. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.
Calleja JL; Albillos A; Moreno-Otero R; Rossi I; Cacho G; Domper F; Yebra M; Escartín P
Aliment Pharmacol Ther; 1999 Sep; 13(9):1179-86. PubMed ID: 10468699
[TBL] [Abstract][Full Text] [Related]
3. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC
Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068
[TBL] [Abstract][Full Text] [Related]
4. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies.
Fabrizi F; Dixit V; Messa P
J Med Virol; 2013 Jun; 85(6):1019-27. PubMed ID: 23588727
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study.
Mazzaro C; Monti G; Saccardo F; Zignego AL; Ferri C; De Vita S; Gabrielli A; Lenzi M; Donada C; Galli M; Pietrogrande M; Pozzato G
Clin Exp Rheumatol; 2011; 29(6):933-41. PubMed ID: 22153224
[TBL] [Abstract][Full Text] [Related]
6. Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review.
Francesca Donato M; Banfi G; Cresseri D; Battista Fogazzi G; Martin P; Messa P; Fabrizi F
Int J Artif Organs; 2013 May; 36(5):367-72. PubMed ID: 23446762
[TBL] [Abstract][Full Text] [Related]
7. [The effect of cryoglobulinemia on the antiviral therapy in patients with chronic hepatitis C].
Fan XH; Wang LF; Liu LC; Yao Y; Shan Y; Lu HY; Wu CH; Xu XY; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):721-5. PubMed ID: 22409840
[TBL] [Abstract][Full Text] [Related]
8. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Resche Rigon M; Pol S; Thibault V; Blanc F; Pialoux G; Karras A; Bazin-Kara D; Cazorla C; Vittecoq D; Musset L; Peltier J; Decaux O; Ziza JM; Lambotte O; Cacoub P
J Hepatol; 2015 Jan; 62(1):24-30. PubMed ID: 25135864
[TBL] [Abstract][Full Text] [Related]
9. Cryoglobulinemia is an independent factor negatively associated with sustained virological response in chronic hepatitis C patients.
Fan XH; Wu CH; Wang LF; Zheng YY; Yao Y; Lu HY; Xu XY; Wei L
Chin Med J (Engl); 2012 Nov; 125(22):4014-7. PubMed ID: 23158135
[TBL] [Abstract][Full Text] [Related]
10. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus.
Levine JW; Gota C; Fessler BJ; Calabrese LH; Cooper SM
J Rheumatol; 2005 Jun; 32(6):1164-7. PubMed ID: 15940780
[TBL] [Abstract][Full Text] [Related]
11. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
Emery JS; Kuczynski M; La D; Almarzooqi S; Kowgier M; Shah H; Wong D; Janssen HLA; Feld JJ
Am J Gastroenterol; 2017 Aug; 112(8):1298-1308. PubMed ID: 28291241
[TBL] [Abstract][Full Text] [Related]
13. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.
Deterding K; Grüner N; Buggisch P; Wiegand J; Galle PR; Spengler U; Hinrichsen H; Berg T; Potthoff A; Malek N; Großhennig A; Koch A; Diepolder H; Lüth S; Feyerabend S; Jung MC; Rogalska-Taranta M; Schlaphoff V; Cornberg M; Manns MP; Wedemeyer H;
Lancet Infect Dis; 2013 Jun; 13(6):497-506. PubMed ID: 23523674
[TBL] [Abstract][Full Text] [Related]
14. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.
Saadoun D; Resche-Rigon M; Thibault V; Piette JC; Cacoub P
Arthritis Rheum; 2006 Nov; 54(11):3696-706. PubMed ID: 17075881
[TBL] [Abstract][Full Text] [Related]
15. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy.
Landau DA; Scerra S; Sene D; Resche-Rigon M; Saadoun D; Cacoub P
J Rheumatol; 2010 Mar; 37(3):615-21. PubMed ID: 20110523
[TBL] [Abstract][Full Text] [Related]
16. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
17. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
Bruchfeld A; Lindahl K; Stahle L; Schvarcz R
J Hepatol; 2006 Feb; 44(2):432-3; author reply 433. PubMed ID: 16338023
[No Abstract] [Full Text] [Related]
18. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P
Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287
[TBL] [Abstract][Full Text] [Related]
19. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.
Gragnani L; Fabbrizzi A; Triboli E; Urraro T; Boldrini B; Fognani E; Piluso A; Caini P; Ranieri J; Monti M; Laffi G; Zignego AL
Dig Liver Dis; 2014 Sep; 46(9):833-7. PubMed ID: 24953206
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients.
Merchante N; de los Santos-Gil I; Merino D; González-Serrano M; Mira JA; Sanz-Sanz J; Fernández-Fuertes E; Ruiz-Morales J; del Valle J; Macías J; Moro A; Pineda JA
J Hepatol; 2009 Apr; 50(4):684-92. PubMed ID: 19231001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
